- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute lymphoblastic leukaemia (ALL)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Blinatumomab – July 2019
Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto®
Last updated
1 November 2019